Sodium, Voltage-Gated Channels

Cambridge Bioscience, through our collaboration with ChanTest, offers access to screening services to the following voltage-gated sodium channel targets:

Nav1.1
Gene Name: SCN1A
Validated Assay/Platform: IonWorks Quattro™ & QPatch HT
Description: The human SCN1A gene encodes the pore-forming subunit of Nav1.1, a voltage-gated sodium channel expressed in CNS neurons and dorsal root ganglia. Mutations in SCN1A cause several types of epilepsies (generalized epilepsy with febrile seizures, severe myoclonic epilepsy in infancy) and some forms of familial hemiplegic migraine. Nav1.1 channels are therapeutic targets in seizure, stroke, and pain.

Nav1.2
Gene Name: SCN2A
Validated Assay/Platform: IonWorks Quattro™ & QPatch HT
Description: The human SCN2A gene encodes the pore-forming subunit of Nav1.2, a voltage-gated sodium channel expressed in CNS neurons. SCN2A mutations are associated with benign familial neonatal-infantile seizures. Nav1.2 channels are therapeutic targets in seizure, stroke, and pain.

Nav1.3
Gene Name: SCN3A
Validated Assay/Platform: IonWorks Quattro™, PatchXpress® & QPatch HT
Description: The human SCN3A gene encodes the pore-forming subunit of Nav1.3, a voltage-gated sodium channel expressed in CNS neurons and upregulated in nerve injury. Nav1.3 channels are therapeutic targets in seizure and pain.

Nav1.4
Gene Name: SCN4A
Validated Assay/Platform: IonWorks Quattro™ & QPatch HT
Description: The human SCN4A gene encodes the pore-forming subunit of Nav1.1, a voltage-gated sodium channel expressed in skeletal muscle. SCN4A mutations cause paramyotonia congenita and hypokalemic periodic paralysis. Nav1.4 are therapeutic targets in myotonia.

Nav1.5
Gene Name: SCN5A
Validated Assay/Platform: IonWorks Quattro™, PatchXpress® & QPatch HT
Description: The human SCN5A gene encodes the pore-forming subunit of Nav1.5, a voltage-gated sodium channel expressed in heart and upregulated in breast cancer cells. Mutations in SCN5A are responsible for some forms of long QT and short QT syndromes, progressive cardiac conduction defect, sick sinus node syndrome, and dilated cardiomyopathy, Brugada syndrome, congenital heart block, Nav1.5 channels are anti-targets in cardiac risk assessment.

Nav1.6
Gene Name: SCN8A
Validated Assay/Platform: IonWorks Quattro™, PatchXpress® & QPatch HT
Description: The human SCN8A gene encodes the pore-forming subunit of Nav1.6, a voltage-gated sodium channel expressed in central and peripheral nervous systems. Mutations in the mouse ortholog cause ataxia and other movement disorders. Nav1.6 channels are therapeutic targets in multiple sclerosis and seizure.

Nav1.8/β3
Gene Name: SCN10A/SCN3B
Validated Assay/Platform: FLIPR®
Description: The human SCN9A gene encodes the pore-forming subunit of Nav1.8, a voltage-gated sodium channel expressed in the peripheral nervous system including dorsal root ganglia. The SCN3B gene encodes an auxiliary β-subunit that promotes surface expression. Nav1.8 channels are upregulated in chronic/inflammatory pain and are therapeutic targets in pain treatment.

Platforms Available
Cambridge Bioscience, through our collaboration with ChanTest, offers access to the widest range of screening platforms, from manual patch clamp up to the most recent innovations in automated electrophysiology, allowing you to select the right balance of speed, throughput and data quality to suit your needs.
To find out more about each of these platforms, please Click Here

Request A No Obligation Quote
To discuss an ion channel screening project, please contact our experienced team by Clicking Here